Cardiovascular Pharmacology: Hypertension and Heart Failure

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/39

flashcard set

Earn XP

Description and Tags

Vocabulary flashcards covering cardiovascular pharmacology, clinical definitions, drug mechanisms, classifications, adverse effects, and guideline recommendations for hypertension and heart failure.

40 Terms

1
New cards

Positive Inotrope

An agent that increases the strength of cardiac muscle contraction.

2
New cards

Negative Inotrope

An agent that decreases the strength of cardiac muscle contraction.

3
New cards

Positive Chronotrope

An agent that increases the rate of cardiac contraction (heart rate).

4
New cards

Negative Chronotrope

An agent that decreases the rate of cardiac contraction (heart rate).

5
New cards

Cardiac Output (CO)

The volume of blood pumped by the heart each minute, calculated as stroke volume multiplied by heart rate (CO=SV×HR\text{CO} = \text{SV} \times \text{HR}).

6
New cards

Ejection Fraction (EF)

A measurement of the percentage of blood the left ventricle pumps out with each cardiac contraction.

7
New cards

Neprilysin

A neutral endopeptidase enzyme that degrades vasoactive substances, including natriuretic peptides, bradykinin, and adrenomedullin.

8
New cards

Natriuretic Peptides (ANP and BNP)

Endogenous peptides that increase endothelial vasodilation, promote renal natriuresis and diuresis, and inhibit myocardial fibrosis and cellular hypertrophy.

9
New cards

Normal Blood Pressure (2025 ACC/AHA)

A blood pressure classification defined as systolic blood pressure <120 mm Hg< 120\text{ mm Hg} and diastolic blood pressure <80 mm Hg< 80\text{ mm Hg}.

10
New cards

Elevated Blood Pressure (2025 ACC/AHA)

A blood pressure classification defined as systolic blood pressure of 120 to 129 mm Hg120\text{ to }129\text{ mm Hg} and diastolic blood pressure <80 mm Hg< 80\text{ mm Hg}.

11
New cards

Stage 1 Hypertension (2025 ACC/AHA)

A blood pressure category defined as systolic blood pressure of 130 to 139 mm Hg130\text{ to }139\text{ mm Hg} or diastolic blood pressure of 80 to 89 mm Hg80\text{ to }89\text{ mm Hg}.

12
New cards

Stage 2 Hypertension (2025 ACC/AHA)

A blood pressure category defined as systolic blood pressure ≄140 mm Hg\ge 140\text{ mm Hg} or diastolic blood pressure ≄90 mm Hg\ge 90\text{ mm Hg}.

13
New cards

Hypertensive Emergency

Severely elevated blood pressure (typically systolic ≄180 mm Hg\ge 180\text{ mm Hg} and/or diastolic ≄120 mm Hg\ge 120\text{ mm Hg}) accompanied by acute, ongoing target organ damage, managed with parenteral agents in an intensive care setting.

14
New cards

Hypertensive Urgency

Severely elevated blood pressure (systolic ≄180 mm Hg\ge 180\text{ mm Hg} and/or diastolic ≄110 mm Hg\ge 110\text{ mm Hg}) in the absence of acute target organ damage, typically managed using oral antihypertensive medications over 24 to 48 hours24\text{ to }48\text{ hours}.

15
New cards

Treatment Resistant Hypertension

Blood pressure that remains ≄130/80 mm Hg\ge 130/80\text{ mm Hg} despite concurrent therapy with three antihypertensive drug classes of complementary mechanisms (including a diuretic) at maximally tolerated doses, or blood pressure controlled only with four or more medications.

16
New cards

Pseudoresistant Hypertension

An apparent lack of blood pressure control caused by external confounders such as poor medication adherence, inaccurate measuring technique, white-coat effect, or suboptimal dosing regimens rather than true physiological resistance.

17
New cards

Angiotensin Converting Enzyme Inhibitors (ACE-I)

Antihypertensive agents that block the conversion of angiotensin I to angiotensin II and reduce bradykinin degradation, leading to vasodilation, reduced aldosterone release, and adverse effects including dry cough and angioedema.

18
New cards

Angiotensin II Receptor Blockers (ARBs)

Antihypertensive agents that selectively antagonize the angiotensin type 1 (AT1\text{AT}_1) receptor to block angiotensin II vasoconstriction and aldosterone release without altering bradykinin breakdown.

19
New cards

Direct Renin Inhibitor (DRI)

A drug class represented by aliskiren that directly blocks renin activity, preventing the enzymatic conversion of angiotensinogen to angiotensin I.

20
New cards

Loop Diuretics

High-ceiling diuretics that compete with chloride at the Na+/K+/2Cl−\text{Na}^+/\text{K}^+/2\text{Cl}^- cotransporter in the thick ascending limb of the loop of Henle, producing marked urinary loss of sodium, chloride, calcium, and magnesium.

21
New cards

Thiazide Diuretics

Sulfonamide-derived diuretics that inhibit the Na+/Cl−\text{Na}^+/\text{Cl}^- cotransporter in the distal convoluted tubule, producing hyperosmolar urine and uniquely enhancing calcium reabsorption.

22
New cards

Mineralocorticoid Receptor Antagonists (MRAs)

Potassium-sparing agents that antagonize aldosterone at intracellular mineralocorticoid receptors in the renal collecting duct, mitigating aldosterone-mediated fibrosis, remodeling, and potassium wasting.

23
New cards

Dihydropyridine Calcium Channel Blockers

A sub-class of calcium channel blockers (e.g., amlodipine, nifedipine) that preferentially bind L-type voltage-sensitive calcium channels in vascular smooth muscle to cause peripheral arteriolar dilation.

24
New cards

Non-Dihydropyridine Calcium Channel Blockers

Calcium channel blockers (verapamil and diltiazem) that act on both vascular smooth muscle and myocardium to exert prominent negative inotropic and negative chronotropic effects.

25
New cards

Cardioselective (ÎČ1\beta_1-Selective) Beta-Blockers

Second-generation beta-adrenergic blockers (e.g., metoprolol, atenolol, bisoprolol) that predominantly antagonize ÎČ1\beta_1 receptors, lowering heart rate and myocardial contractility with minimal ÎČ2\beta_2-mediated bronchoconstriction.

26
New cards

Mixed Alpha/Beta-Adrenergic Blockers

Third-generation beta-blockers (carvedilol and labetalol) that combine non-selective beta-blockade with α1\alpha_1-adrenergic receptor antagonism, lowering peripheral vascular resistance alongside heart rate.

27
New cards

Clevidipine (Cleviprex)

An intravenous-only, ultra-short-acting dihydropyridine calcium channel blocker formulated in a lipid emulsion, with onset within 2 to 4 minutes2\text{ to }4\text{ minutes}, contraindicated in patients with egg or soy allergies.

28
New cards

Esmolol

An intravenous-only, cardioselective ÎČ1\beta_1-blocker rapidly hydrolyzed by serum esterases, yielding an elimination half-life of approximately 8 minutes8\text{ minutes}.

29
New cards

Sodium Nitroprusside

A direct arterial and venous vasodilator that rapidly releases nitric oxide or stimulates guanylyl cyclase, carrying a potential risk of cyanide toxicity with prolonged or high-dose intravenous infusion.

30
New cards

Entresto (Sacubitril/Valsartan)

An angiotensin receptor-neprilysin inhibitor (ARNi) combination that increases vasoactive natriuretic peptides while blocking the AT1\text{AT}_1 receptor, used as foundational therapy in HFrEF.

31
New cards

36-Hour Washout Period

The mandatory time interval required between discontinuing an ACE inhibitor and administering the first dose of Entresto (sacubitril/valsartan) to prevent angioedema.

32
New cards

Finerenone (Kerendia)

A non-steroidal mineralocorticoid receptor antagonist indicated to reduce the risk of cardiovascular events, worsening heart failure, and CKD progression in type 2 diabetes and HF.

33
New cards

Ivabradine (Corlanor)

A selective inhibitor of the cardiac pacemaker hyperpolarization-activated cyclic nucleotide-gated (IfI_f) current in the SA node that reduces heart rate without altering contractility or blood pressure.

34
New cards

Digoxin (Lanoxin)

A digitalis glycoside that inhibits the myocardial Na+/K+-ATPase\text{Na}^+/\text{K}^+\text{-ATPase} pump, raising intracellular sodium and calcium to increase contractile force while slowing conduction across the AV node.

35
New cards

Dobutamine (Dobutrex)

A ÎČ1\beta_1-adrenergic agonist that elevates intracellular cAMP and calcium influx, utilized as an intravenous inotrope for acute inpatient heart failure and cardiogenic shock.

36
New cards

Stage A Heart Failure

A heart failure classification describing patients at high risk for heart failure without current or prior symptoms, structural cardiac disease, or abnormal biomarkers.

37
New cards

Stage B Heart Failure (Pre-Heart Failure)

A heart failure classification encompassing patients without historical or current HF symptoms who demonstrate structural heart disease, elevated filling pressures, or elevated troponin/natriuretic peptides.

38
New cards

Stage C Heart Failure

A clinical stage characterized by current or previous symptomatic heart failure associated with underlying structural heart disease (such as reduced left ventricular ejection fraction).

39
New cards

Evidence-Based Beta-Blockers in HFrEF

The three beta-blockers clinically proven to decrease morbidity and mortality in symptomatic HFrEF: metoprolol succinate, carvedilol, and bisoprolol.

40
New cards

Foundational Guideline-Directed Medical Therapy (GDMT) for HFrEF

The quadruple medical regimen consisting of a RAAS inhibitor (preferably an ARNi), an evidence-based beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.